Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin crossover trial in frontotemporal dementia
ACTRN12618001807246Phase 3Terminated
- Sponsor
- The University of Sydney
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxytocin in frontotemporal dementia (FTD) (2 arms), sponsored by The University of Sydney. Primary endpoints: The Awareness of Social Inference Test and Cambridge Behavioural Inventory. Started Feb 2020; status: terminated.
02
Drugs
oxytocin
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on ACTRN12618001807246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001807246.